Table 2.
Statistical comparison (unpaired t-test) of the clinical effects between the treatment modalities after 42 days (values are given as mean (SD))
| Group | Reduction | Group | Reduction | Significance |
|---|---|---|---|---|
| PI score | ||||
| SRP+Prodentis | 0.76 (0.29) | SRP+placebo | 0.27 (0.13) | p<0.001 |
| SRP+Prodentis | 0.76 (0.29) | Prodentis | 0.41 (0.16) | p<0.001 |
| SRP+placebo | 0.27 (0.13) | Placebo | 0.17 (0.14) | p<0.05 |
| Prodentis | 0.41 (0.16) | Placebo | 0.17 (0.14) | p<0.001 |
| GI score | ||||
| SRP+Prodentis | 0.84 (0.23) | SRP+placebo | 0.38 (0.23) | p<0.001 |
| SRP+Prodentis | 0.84 (0.23) | Prodentis | 0.53 (0.12) | p<0.001 |
| SRP+placebo | 0.38 (0.23) | Placebo | 0.14 (0.14) | p<0.01 |
| Prodentis | 0.53 (0.12) | Placebo | 0.14 (0.14) | p<0.001 |
| GBI (%) | ||||
| SRP+Prodentis | 70.4 (10.7) | SRP+placebo | 32.5 (10.0) | p<0.001 |
| SRP+Prodentis | 70.4 (10.7) | Prodentis | 48.3 (14.4) | p<0.001 |
| SRP+placebo | 32.5 (10.0) | Placebo | 12.0 (8.7) | p<0.001 |
| Prodentis | 48.3 (14.4) | Placebo | 12.0 (8.7) | p<0.001 |
| PPD (mm) | ||||
| SRP+Prodentis | 1.31 (0.49) | SRP+placebo | 0.49 (0.39) | p<0.001 |
| SRP+Prodentis | 1.31 (0.49) | Prodentis | 0.10 (0.20) | p<0.001 |
| SRP+placebo | 0.49 (0.39) | Placebo | −0.04 (0.23) | p<0.001 |
| Prodentis | 0.10 (0.20) | Placebo | −0.04 (0.23) | ns |
| CAL (mm) | ||||
| SRP+Prodentis | 1.09 (0.62) | SRP+placebo | 0.29 (0.51) | p<0.001 |
| SRP+Prodentis | 1.09 (0.62) | Prodentis | 0.17 (0.26) | p<0.001 |
| SRP+placebo | 0.29 (0.51) | Placebo | −0.05 (0.26) | p<0.05 |
| Prodentis | 0.17 (0.26) | Placebo | −0.05 (0.26) | p<0.05 |